NOVAVAX INC (NVAX) Stock Fundamental Analysis
USA - NASDAQ:NVAX - US6700024010 - Common Stock
9.46 USD
-0.09 (-0.94%)
9.43 USD
-0.03 (-0.32%)
Overall NVAX gets a fundamental rating of 4 out of 10. We evaluated NVAX against 536 industry peers in the Biotechnology industry. There are concerns on the financial health of NVAX while its profitability can be described as average. NVAX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
NVAX had positive earnings in the past year.
In the past year NVAX has reported a negative cash flow from operations.
In the past 5 years NVAX always reported negative net income.
In the past 5 years NVAX reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 31.64%, NVAX belongs to the top of the industry, outperforming 98.51% of the companies in the same industry.
NVAX has a Return On Equity of 1123.78%. This is amongst the best in the industry. NVAX outperforms 99.81% of its industry peers.
The Return On Invested Capital of NVAX (30.55%) is better than 98.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| ROIC | 30.55% |
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVAX has a Profit Margin of 39.20%. This is amongst the best in the industry. NVAX outperforms 97.76% of its industry peers.
NVAX has a better Operating Margin (33.97%) than 97.95% of its industry peers.
NVAX has a Gross Margin of 88.30%. This is amongst the best in the industry. NVAX outperforms 89.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.97% | ||
| PM (TTM) | 39.2% | ||
| GM | 88.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), NVAX is creating value.
NVAX has more shares outstanding than it did 1 year ago.
NVAX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NVAX has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.69, we must say that NVAX is in the distress zone and has some risk of bankruptcy.
NVAX's Altman-Z score of -1.69 is in line compared to the rest of the industry. NVAX outperforms 51.68% of its industry peers.
NVAX has a Debt/Equity ratio of 5.93. This is a high value indicating a heavy dependency on external financing.
NVAX has a Debt to Equity ratio of 5.93. This is amonst the worse of the industry: NVAX underperforms 82.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.93 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.69 |
ROIC/WACC3.02
WACC10.1%
2.3 Liquidity
NVAX has a Current Ratio of 2.36. This indicates that NVAX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.36, NVAX is not doing good in the industry: 70.52% of the companies in the same industry are doing better.
A Quick Ratio of 2.34 indicates that NVAX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.34, NVAX is not doing good in the industry: 68.28% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.34 |
3. Growth
3.1 Past
NVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 171.01%, which is quite impressive.
Looking at the last year, NVAX shows a quite strong growth in Revenue. The Revenue has grown by 9.22% in the last year.
Measured over the past years, NVAX shows a very strong growth in Revenue. The Revenue has been growing by 105.31% on average per year.
EPS 1Y (TTM)171.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.37%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-42.42%
3.2 Future
Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.77% on average per year.
The Revenue is expected to decrease by -9.90% on average over the next years.
EPS Next Y246.11%
EPS Next 2Y43.13%
EPS Next 3Y23.51%
EPS Next 5Y17.77%
Revenue Next Year57.02%
Revenue Next 2Y-18.29%
Revenue Next 3Y-27.59%
Revenue Next 5Y-9.9%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 4.83, which indicates a rather cheap valuation of NVAX.
Based on the Price/Earnings ratio, NVAX is valued cheaper than 98.69% of the companies in the same industry.
When comparing the Price/Earnings ratio of NVAX to the average of the S&P500 Index (27.86), we can say NVAX is valued rather cheaply.
A Price/Forward Earnings ratio of 117.61 indicates a quite expensive valuation of NVAX.
Based on the Price/Forward Earnings ratio, NVAX is valued cheaply inside the industry as 86.57% of the companies are valued more expensively.
NVAX is valuated expensively when we compare the Price/Forward Earnings ratio to 23.32, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.83 | ||
| Fwd PE | 117.61 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NVAX indicates a rather cheap valuation: NVAX is cheaper than 99.25% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.95 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NVAX's earnings are expected to grow with 23.51% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y43.13%
EPS Next 3Y23.51%
5. Dividend
5.1 Amount
NVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
9.46
-0.09 (-0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners58.63%
Inst Owner Change2.86%
Ins Owners0.41%
Ins Owner Change5.15%
Market Cap1.54B
Analysts72.86
Price Target13.55 (43.23%)
Short Float %30.18%
Short Ratio6.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)483.55%
Min EPS beat(2)306.88%
Max EPS beat(2)660.22%
EPS beat(4)3
Avg EPS beat(4)228.68%
Min EPS beat(4)-58.31%
Max EPS beat(4)660.22%
EPS beat(8)5
Avg EPS beat(8)86.86%
EPS beat(12)7
Avg EPS beat(12)38.5%
EPS beat(16)7
Avg EPS beat(16)-17.35%
Revenue beat(2)2
Avg Revenue beat(2)74.3%
Min Revenue beat(2)58.52%
Max Revenue beat(2)90.08%
Revenue beat(4)4
Avg Revenue beat(4)40.88%
Min Revenue beat(4)2.61%
Max Revenue beat(4)90.08%
Revenue beat(8)5
Avg Revenue beat(8)18.46%
Revenue beat(12)7
Avg Revenue beat(12)18.88%
Revenue beat(16)7
Avg Revenue beat(16)2.76%
PT rev (1m)-8.82%
PT rev (3m)-12.26%
EPS NQ rev (1m)9.13%
EPS NQ rev (3m)-9.06%
EPS NY rev (1m)4.66%
EPS NY rev (3m)-8.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-45.45%
Revenue NY rev (1m)-0.54%
Revenue NY rev (3m)2.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.83 | ||
| Fwd PE | 117.61 | ||
| P/S | 1.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 40.84 | ||
| P/tB | N/A | ||
| EV/EBITDA | 1.95 |
EPS(TTM)1.96
EY20.72%
EPS(NY)0.08
Fwd EY0.85%
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.88
OCFYN/A
SpS6.64
BVpS0.23
TBVpS-0.46
PEG (NY)0.02
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| ROCE | 38.67% | ||
| ROIC | 30.55% | ||
| ROICexc | 86.37% | ||
| ROICexgc | 130.29% | ||
| OM | 33.97% | ||
| PM (TTM) | 39.2% | ||
| GM | 88.3% | ||
| FCFM | N/A |
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.93 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.55 | ||
| Cap/Depr | 11.6% | ||
| Cap/Sales | 0.44% | ||
| Interest Coverage | 18.14 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.34 | ||
| Altman-Z | -1.69 |
F-Score6
WACC10.1%
ROIC/WACC3.02
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)171.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.37%
EPS Next Y246.11%
EPS Next 2Y43.13%
EPS Next 3Y23.51%
EPS Next 5Y17.77%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-42.42%
Revenue Next Year57.02%
Revenue Next 2Y-18.29%
Revenue Next 3Y-27.59%
Revenue Next 5Y-9.9%
EBIT growth 1Y228.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year310.32%
EBIT Next 3Y13.97%
EBIT Next 5YN/A
FCF growth 1Y13.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.53%
OCF growth 3YN/A
OCF growth 5YN/A